Estrogen
Estrogens (+)
Example (R): Raloxifene
Estrogens play a vital role throughout a female's reproductive life, particularly in maintaining bone integrity.
They inhibit cytokines that recruit osteoclasts, which are cells responsible for bone resorption, and oppose the bone-resorbing, calcium-mobilizing actions of parathyroid hormone (PTH).
Mechanism of Action (MoA):
Estrogens are effective in preventing accelerated bone loss during the immediate postmenopausal period.
They can at least transiently increase bone mass in postmenopausal women, which is crucial for maintaining bone density and preventing osteoporosis.
These hormones reduce the bone-resorbing action of PTH, thereby favoring a balance towards bone formation rather than destruction.
Administration of estrogens leads to an increase in the levels of 1,25-dihydroxyvitamin D (1.25(OH)2D) in the blood.
This rise can be attributed to decreased serum calcium and phosphate levels along with an increase in PTH.
Estrogen receptors, which mediate the effects of estrogens, have been identified in bone tissue, indicating that estrogens have direct effects on bone remodeling processes.
Pharmacokinetics:
Estrogens are well absorbed in the gastrointestinal tract (GIT) and are widely distributed in various tissues.
They are converted to active metabolites primarily in the (LLSK) liver, lungs, spleen, and kidneys.
The average half-life of estrogens is approximately 32 hours, allowing for sustained action in the body.
Excretion occurs primarily via feces.
Uses (HP):
Hormone replacement therapy (HRT) for alleviating menopausal symptoms.
Prevention and treatment of postmenopausal osteoporosis, an important consideration given the increased risk of fractures in this population.
Side Effects (HLV):
Common side effects include hot flashes and leg cramps, which some patients may experience with hormone therapy.
There is a potential risk of venous thromboembolism, which necessitates careful patient selection and monitoring during treatment.